The placebo-controlled trial examined the safety and tolerability of three doses of VP025, Vasogen’s drug candidate, in 24 healthy volunteers. Multiple administrations of either low, mid, or high doses of VP025 were shown to be safe and well tolerated when compared to placebo and no drug-related serious adverse events were reported.
David Elsley, president and CEO of Vasogen said: “VP025 offers the potential for new growth opportunities and provides a strong complement to our lead product, the Celacade technology, which is currently in the final stages of two pivotal phase III clinical trials in patients with chronic heart failure and peripheral arterial disease.”
Mr Elsley expressed the company’s desire to further develop VP025 by assessing its effects in patients with neuro-inflammatory disorders.